Can Tikva Allocell’s $8m bet solve the persistence problem holding back off-the-shelf CAR-T?
Tikva Allocell raises $8 million to advance TAVST01 toward an IND, testing an EBV-specific CAR-T approach for B7-H3-positive solid tumors.
Pharma & Biotech
Pharma & Biotech
Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.
Pharma & Biotech
Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?
Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.
Pharma & Biotech
Can bispecific ADCs give NEOK Bio a more credible route into solid tumor drug development?
NEOK Bio unveiled AACR 2026 data for NEOK001 and NEOK002. Read how its bispecific ADC strategy could reshape solid tumor competition.
Pharma & Biotech
Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors
GT Biopharma's GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
Pharma & Biotech
GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.
Pharma & Biotech
Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
Pharma & Biotech
T-MAXIMUM’s MT027 clears FDA hurdle for glioblastoma in major step for solid tumor CAR-T
T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.